Discussing the Debate: Leukocyte-Rich Platelet-Rich Plasma Versus Leukocyte-Poor Platelet-Rich Plasma.

leukocyte-poor prp leukocyte-rich prp leukocyte-rich vs. leukocyte-poor platelet-rich plasma leukocytes platelet-rich plasma (prp)

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Apr 2024
Historique:
accepted: 16 04 2024
medline: 17 5 2024
pubmed: 17 5 2024
entrez: 17 5 2024
Statut: epublish

Résumé

This editorial touches on the persistent debate related to platelet-rich plasma (PRP) therapy. It focuses on the different approaches involving leukocyte-rich and leukocyte-poor PRP formulations of the PRP. It looks into the reasons behind these approaches, their potential effects on clinical practice, i.e., pros and cons, and the evidence supporting each method within the field of regenerative medicine. Examining these different views highlights the complexity of PRP therapy. It's important to proceed carefully, relying on evidence to enhance patient outcomes. Understanding the ongoing debates can help healthcare professionals make informed decisions. We need to consider various factors before implementing PRP therapy, ensuring it's done responsibly.

Identifiants

pubmed: 38756260
doi: 10.7759/cureus.58381
pmc: PMC11097227
doi:

Types de publication

Editorial

Langues

eng

Pagination

e58381

Informations de copyright

Copyright © 2024, Yadav et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Sankalp Yadav (S)

Medicine, Shri Madan Lal Khurana Chest Clinic, New Delhi, IND.

Classifications MeSH